Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Equity Average (2016 - 2025)

Historic Equity Average for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $217.4 million.

  • Amicus Therapeutics' Equity Average rose 3962.77% to $217.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.4 million, marking a year-over-year increase of 3962.77%. This contributed to the annual value of $177.1 million for FY2024, which is 2506.81% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Equity Average stood at $217.4 million, which was up 3962.77% from $198.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Equity Average ranged from a high of $342.0 million in Q4 2021 and a low of $107.1 million during Q2 2023
  • Moreover, its 5-year median value for Equity Average was $186.4 million (2024), whereas its average is $190.3 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Equity Average crashed by 6262.97% in 2022, and later surged by 5115.36% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Equity Average (Quarter) stood at $342.0 million in 2021, then tumbled by 62.63% to $127.8 million in 2022, then grew by 14.79% to $146.7 million in 2023, then grew by 27.08% to $186.4 million in 2024, then increased by 16.59% to $217.4 million in 2025.
  • Its last three reported values are $217.4 million in Q3 2025, $198.9 million for Q2 2025, and $193.8 million during Q1 2025.